Abstract #1897

GRAPPATINI T2 Mapping to Predict Dopamine Agonist Resistance in Prolactinomas: A Pilot study

Rong Lu¹, Lijin Ji², Tingfang Hwang¹, Qing Li³, Caixia Fu⁴, Ying-Hua Chu³, Tobias Kober^5,6,7, Tom Hilbert^5,6,7, Shangxuan Shi⁸, Bin Lu^2,9, He Wang^10,11,12, and Weijun Tang¹

¹Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China, ²Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China, ³MR Research Collaboration, Siemens Healthineers Ltd., Shanghai, China, ⁴Application Developments, Siemens Shenzhen Magnetic Resonance Ltd., Shenzhen, China, ⁵Advanced Clinical Imaging Technology, Siemens Healthineers International AG, Lausanne, Switzerland, ⁶LTS5, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland, ⁷Department of Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, ⁸ShanghaiTech University, Shanghai, China, ⁹Department of Endocrinology, Huadong Hospital, Fudan University, Shanghai, China, ¹⁰Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China, ¹¹Human Phenome Institute, Fudan University, Shanghai, China, ¹²Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence (Fudan University), Ministry of Education, Shanghai, China

Synopsis

Keywords: Head & Neck/ENT, Tumors, prolactinoma

Motivation: Managing dopamine agonist (DA) resistance in prolactinoma is challenging, with no reliable imaging markers for prediction.

Goal(s): This study used accelerated quantitative T2 mapping (GRAPPATINI) to evaluate DA sensitivity in prolactinoma patients.

Approach: This cross-sectional study analyzed the diagnostic performance of T2 values with multiple echo times (TEs) and signal intensity (SI) ratios to predict drug sensitivity between drug-resistant and sensitive groups.

Results: The study elucidated significantly reduced T2 values in patients with DA-resistant prolactinoma, reaching an area under the curve (AUC) of 0.850 for accurately distinguishing DA sensitivity, with pronounced differences observed at TE38ms. Conversely, T2 SI ratios showed no statistical significance.

Impact: This pilot study was novel in using GRAPPATINI in prolactinoma. Quantitative T2 values of tumors were lower in patients with DA-resistant prolactinoma. Hence, T2 values may be a promising predictive imaging biomarker for DA sensitivity.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.